Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Inflammation and Tissue Damage Mediated By PAR-1 Expression Is Cell Type-Specific and Varies Depending on the Inflammatory Challenge

Alexander A Boucher, MD, Leah A. Rosenfeldt, BS, Duaa Mureb, BS, Anna K Kopec, PhD, James P. Luyendyk, PhD, Matthew J. Flick, PhD, Joseph S. Palumbo, MD

Blood (2018) 132 (Supplement 1): 133.

https://doi.org/10.1182/blood-2018-99-117312

Published: 2018

Journal Articles

Systematic Review of Infectious Events in Prospective Trials of Ibrutinib

Benjamin Tillman, MD, James Michael Pauff, MD PhD, Gowri Satyanarayana, MD, Mahsa Sharifi Talbott, PharmD, Jeremy Warner, MD MS

Blood (2017) 130 (Supplement 1): 3460.

https://doi.org/10.1182/blood.V130.Suppl_1.3460.3460

Published: 2017

Journal Articles

The Utility of Repeated Endoscopy in Patients with Gastrointestinal Graft-Versus-Host Disease: Single Center Retrospective Analysis

Ehsan Shabbir, MD, Sarah Mott, MS, Lindsay Dozeman, Umar Farooq, MD, Margarida Silverman, MD

Blood (2017) 130 (Supplement 1): 5487.

https://doi.org/10.1182/blood.V130.Suppl_1.5487.5487

Published: 2017

Journal Articles

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Alison J. Moskowitz, MD, Raphael Koch, MD, Neha Mehta-Shah, MD, Patricia Myskowski, MD, Meenal Kheterpal, MD, Ahmet Dogan, MD PhD, Theresa Davey, MPAS, Natasha Galasso, BA, Marzouk Evan, BA, Monica Shah, BA, Nivetha Ganesan, BS, Lakeisha Lubin, BS, Youn H. Kim, MD, Michael Khodadoust, MD PhD, Timothy Almazan, MD, Julia Dai, MD, Eric D. Jacobsen, MD, David M. Weinstock, MD, Steven M. Horwitz, MD

Blood (2017) 130 (Supplement 1): 819.

https://doi.org/10.1182/blood.V130.Suppl_1.819.819

Published: 2017

Journal Articles

The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma

Jeffrey J. Pu, MD PhD, W. Christopher Ehmann, MD, Jason Liao, PhD, Christine Capper, BSN, Michelle Levy, MD, David F. Claxton, MD, Witold B. Rybka, MD, Raymond J. Hohl, MD PhD, Elliot M. Epner, MD PhD

Blood (2016) 128 (22): 1792.

https://doi.org/10.1182/blood.V128.22.1792.1792

Published: 2016

Journal Articles

Feasibility and Efficacy of Administration of Bortezomib-Containing Regimens to Patients Over the Age of 70 Years

Christopher Parrish, MA, MB, BChir, MRCP, Julian Cromack, Sylvia Feyler, MD, MRCP, FRCPath, John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Roger G. Owen, MD, Gordon Cook, MD

Blood (2010) 116 (21): 5035.

https://doi.org/10.1182/blood.V116.21.5035.5035

Published: 2010

Journal Articles

A Study of Factors Influencing Outcome In Patients with Haematological Malignancy Requiring High Dependency Support In a Large UK Haematology and Bone Marrow Transplant Centre

Satarupa Choudhuri, Tim Somervaille, Phil Haji Michael, Mike Dennis

Blood (2010) 116 (21): 4732.

https://doi.org/10.1182/blood.V116.21.4732.4732

Published: 2010

Journal Articles

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Steven Grant, MD, Sarah Kolla, Leonardo Andres Sirulnik, MD, PhD, Geoffrey Shapiro, Jeffrey Supko, Brenda Cooper, Edward Perkins, Viswanathan Ramakrishnan, Igor Espinoza-Delgado, MD, M B Tombes, John D Roberts

Blood (2008) 112 (11): 2986.

https://doi.org/10.1182/blood.V112.11.2986.2986

Published: 2008

Journal Articles

Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.

Corey Cutler, MD MPH FRCPC, David Miklos, MD PhD, Stephanie J. Lee, MD MPH, Sook-Bin Woo, DMD, Nathaniel Treister, DMD, Don Bienfang, MD, Lloyd Klickstein, MD PhD, Jesse Levin, BA, Katherine H. Miller, BA, Carol Reynolds, PhD, Mildred Pasek, RN, Vincent Ho, MD, Jerome Ritz, MD PhD, Joseph H. Antin, MD, Robert Soiffer, MD, Edwin Alyea, MD

Blood (2004) 104 (11): 2251.

https://doi.org/10.1182/blood.V104.11.2251.2251

Published: 2004

NARROW

Inflammation and Tissue Damage Mediated By PAR-1 Expression Is Cell Type-Specific and Varies Depending on the Inflammatory Challenge

Systematic Review of Infectious Events in Prospective Trials of Ibrutinib

The Utility of Repeated Endoscopy in Patients with Gastrointestinal Graft-Versus-Host Disease: Single Center Retrospective Analysis

In Vitro , In Vivo , and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma

Feasibility and Efficacy of Administration of Bortezomib-Containing Regimens to Patients Over the Age of 70 Years

A Study of Factors Influencing Outcome In Patients with Haematological Malignancy Requiring High Dependency Support In a Large UK Haematology and Bone Marrow Transplant Centre

Phase I Trial of Vorinostat (SAHA) in Combination with Alvocidib (Flavopiridol) in Patients with Relapsed, Refractory or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia with Excess Blasts-2 (RAEB-2)

Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only